CLINICAL PRACTICE. Generalized Anxiety Disorder.

Key Clinical PointsGeneralized Anxiety Disorder Generalized anxiety disorder is characterized by persistent anxiety and uncontrollable worry that occurs consistently for at least 6 months. This disorder is commonly associated with depression, alcohol and substance abuse, physical health problems, or all these factors. In primary care, patients with this disorder often present with physical symptoms such as headaches, muscle tension, gastrointestinal symptoms, back pain, and insomnia. Brief validated screening tools such as the Generalized Anxiety Disorder 7 (GAD-7) scale should be used to assess the severity of symptoms and response to treatment. First-line treatments for generalized anxiety disorder are cognitive behavioral therapy, pharmacotherapy with a selective serotonin-reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI), or cognitive behavioral therapy in conjunction with either an SSRI or an SNRI. Pregabalin and buspirone are suitable second-line or adjunctive medicat...

[1]  Michael E. Miller,et al.  Telephone-Delivered Cognitive Behavioral Therapy and Telephone-Delivered Nondirective Supportive Therapy for Rural Older Adults With Generalized Anxiety Disorder: A Randomized Clinical Trial. , 2015, JAMA psychiatry.

[2]  D. Baldwin,et al.  Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature , 2015, Journal of psychopharmacology.

[3]  K. Rickels,et al.  Pharmacological treatment for generalized anxiety disorder in adults: an update , 2015, Expert opinion on pharmacotherapy.

[4]  J. Krystal,et al.  Restricting Benzodiazepines to Short-Term Prescription. , 2015, JAMA psychiatry.

[5]  M. Paulus,et al.  Intolerance of uncertainty as a mediator of reductions in worry in a cognitive behavioral treatment program for generalized anxiety disorder. , 2015, Journal of anxiety disorders.

[6]  P. de Jonge,et al.  Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses. , 2015, JAMA psychiatry.

[7]  Antoine Pariente,et al.  Is there really a link between benzodiazepine use and the risk of dementia? , 2015, Expert opinion on drug safety.

[8]  M. Thase,et al.  A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER , 2015, Depression and anxiety.

[9]  J. Welge,et al.  EFFICACY AND TOLERABILITY OF ANTIDEPRESSANTS IN PEDIATRIC ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META‐ANALYSIS , 2015, Depression and anxiety.

[10]  J. Hettema,et al.  Direct, indirect and pleiotropic effects of candidate genes on internalizing disorder psychopathology , 2015, Psychological Medicine.

[11]  Tiffany-Jade Kreys,et al.  A Literature Review of Quetiapine for Generalized Anxiety Disorder , 2015, Pharmacotherapy.

[12]  A. Simmons,et al.  Common and disorder-specific neural responses to emotional faces in generalised anxiety, social anxiety and panic disorders , 2015, British Journal of Psychiatry.

[13]  A. Simmons,et al.  Cognitive-behavioral therapy for generalized anxiety disorder is associated with attenuation of limbic activation to threat-related facial emotions. , 2014, Journal of affective disorders.

[14]  M. Roca,et al.  Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: a systematic review of cohort studies. , 2014, Journal of affective disorders.

[15]  C. Grillon,et al.  The dorsal medial prefrontal (anterior cingulate) cortex–amygdala aversive amplification circuit in unmedicated generalised and social anxiety disorders: an observational study , 2014 .

[16]  P. Blier,et al.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders , 2014, BMC Psychiatry.

[17]  J. Walkup,et al.  Treatment of separation, generalized, and social anxiety disorders in youths. , 2014, The American journal of psychiatry.

[18]  Ulrike Lueken,et al.  Neural structures, functioning and connectivity in Generalized Anxiety Disorder and interaction with neuroendocrine systems: a systematic review. , 2014, Journal of affective disorders.

[19]  Gerhard Andersson,et al.  Psychological treatment of generalized anxiety disorder: a meta-analysis. , 2014, Clinical psychology review.

[20]  Yinzhong Chen,et al.  A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder , 2014, Human psychopharmacology.

[21]  S. Zisook,et al.  Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. , 2013, The American journal of psychiatry.

[22]  M. Otto,et al.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. , 2013, The Journal of clinical psychiatry.

[23]  Mark B. Powers,et al.  LET'S GET PHYSICAL: A CONTEMPORARY REVIEW OF THE ANXIOLYTIC EFFECTS OF EXERCISE FOR ANXIETY AND ITS DISORDERS , 2013, Depression and anxiety.

[24]  C. Sherbourne,et al.  DIAGNOSTIC OVERLAP OF GENERALIZED ANXIETY DISORDER AND MAJOR DEPRESSIVE DISORDER IN A PRIMARY CARE SAMPLE , 2012, Depression and anxiety.

[25]  M. Paulus,et al.  Prefrontal dysfunction during emotion regulation in generalized anxiety and panic disorders , 2012, Psychological Medicine.

[26]  T. Einarson,et al.  Evidence-Based Review of Clinical Outcomes of Guideline-Recommended Pharmacotherapies for Generalized Anxiety Disorder , 2012, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[27]  H. Möller,et al.  Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care , 2012, International journal of psychiatry in clinical practice.

[28]  J. Sareen,et al.  Suicide attempts versus nonsuicidal self‐injury among individuals with anxiety disorders in a nationally representative sample , 2012, Depression and anxiety.

[29]  Jennifer A. Robinson,et al.  Role of self-medication in the development of comorbid anxiety and substance use disorders: a longitudinal investigation. , 2011, Archives of general psychiatry.

[30]  A. M. Ruscio,et al.  A meta-analysis of the relation of intolerance of uncertainty to symptoms of generalized anxiety disorder, major depressive disorder, and obsessive-compulsive disorder. , 2011, Clinical psychology review.

[31]  C. Sherbourne,et al.  Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. , 2011, Archives of general psychiatry.

[32]  J. Sareen,et al.  Prevalence and correlates of generalized anxiety disorder in a national sample of older adults. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[33]  Andrea Cipriani,et al.  Hydroxyzine for generalised anxiety disorder. , 2010, The Cochrane database of systematic reviews.

[34]  M. Stein,et al.  Burden of anxiety disorders in pediatric medical settings: prevalence, phenomenology, and a research agenda. , 2010, Archives of pediatrics & adolescent medicine.

[35]  Murray B Stein,et al.  The pharmacologic treatment of anxiety disorders: a review of progress. , 2010, The Journal of clinical psychiatry.

[36]  C. Sherbourne,et al.  Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. , 2010, JAMA.

[37]  Alice T. Sawyer,et al.  The effect of mindfulness-based therapy on anxiety and depression: A meta-analytic review. , 2010, Journal of consulting and clinical psychology.

[38]  R. Kessler,et al.  The descriptive epidemiology of commonly occurring mental disorders in the United States. , 2008, Annual review of public health.

[39]  Patrick Monahan,et al.  Anxiety Disorders in Primary Care: Prevalence, Impairment, Comorbidity, and Detection , 2007, Annals of Internal Medicine.

[40]  M. Stein,et al.  Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. , 2006, Archives of internal medicine.

[41]  M. Thase,et al.  Azapirones for generalized anxiety disorder. , 2006, The Cochrane database of systematic reviews.

[42]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[43]  C. Sherbourne,et al.  Functional Impact and Health Utility of Anxiety Disorders in Primary Care Outpatients , 2005, Medical care.

[44]  Michael C Neale,et al.  The structure of genetic and environmental risk factors for anxiety disorders in men and women. , 2005, Archives of general psychiatry.

[45]  F J Durgin,et al.  Depression in the elderly. , 1978, Comprehensive therapy.

[46]  Alishia D. Williams,et al.  Internet-Delivered Cognitive Behavior Therapy for Anxiety Disorders Is Here to Stay , 2014, Current Psychiatry Reports.

[47]  D. Revicki,et al.  The Impact of Medication on Health-Related Quality of Life in Patients with Generalized Anxiety Disorder , 2014, CNS Drugs.